Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Lifecore Biomedical, Inc. LFCR

Healthcare  —  Drug Manufacturers Specialty & Generic
4.20 (0.09) (2.10%) as of 25 Sep
Market cap
$162.4M
P/E
0.0×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Lifecore Biomedical, Inc. (LFCR) Business Profile

Updated before January 2025

Company Overview

Lifecore Biomedical, Inc. (LFCR) is a leading company in the biomedical and pharmaceutical sectors, specializing in the development, manufacturing, and commercialization of innovative products and services. Founded in 1965 and headquartered in Chaska, Minnesota, Lifecore has established itself as a trusted partner for pharmaceutical and medical device companies worldwide. The company operates with a mission to improve patient outcomes through advanced biocompatible materials and cutting-edge manufacturing processes.

Lifecore’s leadership team is composed of experienced professionals with deep expertise in the biomedical and pharmaceutical industries. The company is led by its CEO, James G. Hall, who has been instrumental in driving Lifecore’s strategic growth and innovation. Under his leadership, the company has expanded its product portfolio and strengthened its position as a key player in the industry.

Core Business Segments

Lifecore Biomedical operates across several core business segments, each focused on delivering high-quality products and services to its clients. These segments include:

1. Hyaluronic Acid (HA) Products

Lifecore is a global leader in the production of pharmaceutical-grade hyaluronic acid, a biopolymer widely used in medical and cosmetic applications. Key products in this category include:

  • Ophthalmic Solutions: HA-based solutions for eye surgeries, such as cataract and refractive procedures.
  • Dermal Fillers: HA formulations for aesthetic treatments, including wrinkle reduction and facial contouring.
  • Orthopedic Applications: HA injections for joint lubrication and pain relief in osteoarthritis patients.

2. Contract Development and Manufacturing Organization (CDMO) Services

Lifecore provides end-to-end CDMO services to pharmaceutical and medical device companies. These services include:

  • Formulation Development: Custom formulation of biocompatible materials.
  • Sterile Fill-Finish: Aseptic filling of injectable products.
  • Packaging and Labeling: Comprehensive packaging solutions to meet regulatory requirements.

3. Medical Device Components

The company also manufactures specialized components for medical devices, leveraging its expertise in biocompatible materials and precision engineering.

Business Model

Lifecore Biomedical’s business model is centered on innovation, quality, and collaboration. The company integrates its products and services to provide comprehensive solutions to its clients. Revenue is generated through:

  • Product Sales: Direct sales of HA-based products to healthcare providers and distributors.
  • Service Contracts: Long-term agreements with pharmaceutical and medical device companies for CDMO services.
  • Licensing Agreements: Licensing its proprietary technologies to other companies.

Lifecore’s vertically integrated approach ensures quality control and cost efficiency, enabling the company to deliver value to its clients and maintain a competitive edge.

Strategic Direction

Lifecore Biomedical is committed to driving growth through innovation and sustainability. Key strategic initiatives include:

  • Expansion of CDMO Services: Investing in advanced manufacturing facilities to meet the growing demand for sterile injectable products.
  • Sustainability Goals: Implementing eco-friendly practices in its operations, such as reducing waste and energy consumption.
  • New Product Development: Exploring new applications for hyaluronic acid and other biocompatible materials in emerging medical fields.
  • Global Market Expansion: Strengthening its presence in international markets through strategic partnerships and acquisitions.

Competitive Landscape

Lifecore operates in a highly competitive industry, facing competition from both established players and emerging companies. Key competitors include:

  • Allergan (a subsidiary of AbbVie): A major player in the aesthetic and ophthalmic markets.
  • Sanofi: Known for its HA-based orthopedic products.
  • Catalent: A leading provider of CDMO services.

Despite the competition, Lifecore’s focus on quality, innovation, and customer service has enabled it to maintain a strong market position.

Risk Factors

Lifecore Biomedical faces several risks that could impact its operations and financial performance. These include:

  • Market Dependence: Reliance on a limited number of key clients for a significant portion of its revenue.
  • Regulatory Challenges: Compliance with stringent regulatory requirements in different markets.
  • Supply Chain Disruptions: Potential delays in the procurement of raw materials or disruptions in manufacturing processes.
  • Economic Uncertainty: Fluctuations in global economic conditions that could affect demand for its products and services.

Recent Developments

Lifecore has recently made significant strides in expanding its capabilities and product offerings. Notable developments include:

  • Launch of New HA-Based Products: Introduction of advanced formulations for orthopedic and aesthetic applications.
  • Facility Upgrades: Investment in state-of-the-art manufacturing facilities to enhance production capacity and efficiency.
  • Strategic Partnerships: Collaboration with leading pharmaceutical companies to co-develop innovative products.
  • Response to Global Events: Adaptation of its operations to address challenges posed by the COVID-19 pandemic, including increased demand for sterile injectable products.

Investment Considerations

Investors considering Lifecore Biomedical should weigh the following factors:

Strengths

  • Market Leadership: Strong position in the HA market and CDMO services.
  • Innovation-Driven: Commitment to research and development.
  • Diversified Revenue Streams: Balanced mix of product sales and service contracts.

Risks

  • Client Concentration: Dependence on a few key clients.
  • Regulatory Risks: Potential delays in product approvals.
  • Market Volatility: Exposure to economic and industry-specific fluctuations.

Conclusion

Lifecore Biomedical, Inc. is a well-established company with a strong track record of innovation and quality. Its leadership in the HA market, combined with its expanding CDMO services, positions it for continued growth. While the company faces certain risks, its strategic initiatives and commitment to sustainability make it an attractive option for investors seeking exposure to the biomedical and pharmaceutical sectors.